A new meta-analysis of 6 randomized trials and 3,453 people shows how much atogepant actually reduces monthly migraine days, which dose works best, and what side effects to expect. Doses,...

Twenty-two studies and 14,763 people, pooled: higher screen exposure is linked to about 60% greater odds of migraine or headache, on evidence graded low certainty. The design cannot establish which...

A new BMJ Evidence-Based Medicine review pooled 8 randomized trials of ginger for migraine and graded every outcome as low or very low certainty. Here is what that means and...

A new review of 16 randomized trials breaks down how the gepants atogepant and rimegepant perform for migraine prevention and acute treatment. Here is what the evidence shows on efficacy,...

A nationwide Danish study of 189,392 adults found that starting weight-loss semaglutide was followed by a gradual 7% reduction in triptan use over 12 months. Here is what the findings...

A new BMJ randomized trial in 1,000 adults with migraine and a patent foramen ovale found rivaroxaban beat metoprolol for migraine prevention, with aspirin and clopidogrel close behind. Here is...

A study of nearly one million emergency visits found that wildfire-sourced air pollution was linked to a roughly 6 percent rise in visits for migraine and other primary headache, with...

A new network meta-analysis of 28 randomized trials shows noninvasive neuromodulation devices can cut monthly migraine days without drugs. Here is how they work, which have the strongest evidence, and...

A 2026 meta-analysis pooled only sham-controlled trials and found acupuncture modestly reduced migraine frequency and pain intensity in adults with migraine without aura. Certainty of the evidence was low to...

Migraine hits hardest during the reproductive years. Here is what the latest evidence says about which migraine medications are safe during pregnancy and breastfeeding, from triptans and NSAIDs to topiramate,...

New real-world data on rimegepant for migraine prevention: a 75 mg every-other-day gepant that also treats attacks. What the GEMA study found on response rates, dosing, and why earlier use...

A new Neurology meta-analysis of 126 acute migraine trials found that about 1 in 9 people reach 2-hour pain freedom on placebo alone, and that placebo response has been rising...

A phase 3 open-label extension followed nearly 600 people taking atogepant [Qulipta] for migraine prevention and tracked their weight for a year. Mean weight went down, and about 3 in...

A large new randomized trial shows that personalized low-glycemic nutrition can lower monthly migraine days. Here is what the blood sugar and migraine link means for prevention, and how to...